PE20050415A1 - ALPHA CARBOXYL ACIDS SUBSTITUTED AS PPAR MODULATORS - Google Patents

ALPHA CARBOXYL ACIDS SUBSTITUTED AS PPAR MODULATORS

Info

Publication number
PE20050415A1
PE20050415A1 PE2004000361A PE2004000361A PE20050415A1 PE 20050415 A1 PE20050415 A1 PE 20050415A1 PE 2004000361 A PE2004000361 A PE 2004000361A PE 2004000361 A PE2004000361 A PE 2004000361A PE 20050415 A1 PE20050415 A1 PE 20050415A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
oxazol
phenyl
substituted
Prior art date
Application number
PE2004000361A
Other languages
Spanish (es)
Inventor
Simon Bailey
Paul Stuart Humphries
Wei-Guo Su
Luke Raymond Zehnder
Donald James Skalitzky
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20050415A1 publication Critical patent/PE20050415A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Abstract

SE REFIERE A COMPUESTOS ACIDOS CARBOXILICOS ALFA SUSTITUIDOS DE FORMULA (I), DONDE Q ES ARILO(C6-C10) O HETEROCICLILO DE 4 A 10 ESLABONES; R1 ES H, HALO, ALQUILO(C1-C8), ALCOXI(C1-C8), CN, CF3, -O-CF3-, -O-SO2-ALQUILO(C1-C8), ENTRE OTROS; R2 ES H, ALQUILO(C1-C8), -(CR11R12)t-CICLOALQUILO(C3-C10), ENTRE OTROS DONDE LOS ATOMOS DE C ESTAN OPCIONALMENTE SUSTITUIDOS CON 1 A 3 GRUPOS R13 Y LOS ATOMOS DE N DE R2 PUEDEN ESTAR SUSTITUIDOS POR ALQUILO(C1-C8); R3 ES -R4-Ar1-Ar2-R5-C(R6R7)-R8, -R4-Y-Y"-(C)p(R11R12)-Ar3-R5-C(R6R7R8), ENTRE OTROS, DONDE CADA Ar ES ARILO(C6-C10) O HETEROCICLILO(C5-C10) ESLABONES OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: ACIDO 1-({3´-[2-(5-METIL-2-FENIL-1,3-OXAZOL-4-IL)ETOXI]-1,1´-BIFENIL-3-IL}OXI)CICLOBUTANOCARBOXILICO, ACIDO 2-METIL-2-{3-[({[2-(5-METIL-2-FENIL-1,3-OXAZOL-4-IL)ETOXI]CARBONIL}AMINO)METIL]FENOXI}PROPANOICO, ACIDO 2-ETOXI-3-{6-{2-(5-METIL-2-FENIL-1,3-OXAZOL-4-IL)ETOXI]PIRIDIN-3-IL}PROPANOICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS MODULAN LA ACTIVIDAD DEL RECEPTOR ACTIVADO-PROLIFERADOR DE PEROXISOMAS (PPAR) Y SON UTILES PARA MODULAR LA GLUCOSA EN SANGRE E INCREMENTAR LA SENSIBILIDAD A INSULINA, PARA EL TRATAMIENTO DE DIABETES, DISLIPIDEMIA OBESIDAD Y TRANSTORNOS INFLAMATORIOSREFERS TO ALPHA CARBOXYL ACID COMPOUNDS SUBSTITUTED FOR FORMULA (I), WHERE Q IS ARYL (C6-C10) OR 4 TO 10-LINK HETEROCICLYL; R1 IS H, HALO, ALKYL (C1-C8), ALCOXY (C1-C8), CN, CF3, -O-CF3-, -O-SO2-ALKYL (C1-C8), AMONG OTHERS; R2 IS H, ALKYL (C1-C8), - (CR11R12) t-CYCLOALKYL (C3-C10), AMONG OTHERS WHERE THE C ATOMS ARE OPTIONALLY REPLACED WITH 1 TO 3 R13 GROUPS AND THE N ATOMS OF R2 MAY BE SUBSTITUTED BY ALKYL (C1-C8); R3 IS -R4-Ar1-Ar2-R5-C (R6R7) -R8, -R4-YY "- (C) p (R11R12) -Ar3-R5-C (R6R7R8), AMONG OTHERS, WHERE EACH Ar IS ARYL ( C6-C10) OR HETERO CYCLYL (C5-C10) OPTIONALLY SUBSTITUTED LINKS ARE PREFERRED COMPOUNDS: ACID 1 - ({3´- [2- (5-METHYL-2-PHENYL-1,3-OXAZOL-4-IL) ETOXY ] -1,1'-BIPHENYL-3-IL} OXY) CYCLOBUTANOCARBOXYL, 2-METHYL-2- {3 - [({[2- (5-METHYL-2-PHENYL-1,3-OXAZOL-4- IL) ETOXY] CARBONYL} AMINO) METHYL] PHENOXY} PROPANOIC, 2-ETHOXY-3- {6- {2- (5-METHYL-2-PHENYL-1,3-OXAZOL-4-IL) ETHOXY] PYRIDIN- 3-IL} PROPANOIC, AMONG OTHERS. ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS MODULATE THE ACTIVITY OF THE ACTIVATED PEROXISOME-PROLIFERATOR-RECEPTOR (PPAR) AND ARE USEFUL TO MODULATE BLOOD GLUCOSE AND INCREASE SENSIN TREATMENT OF DIABETES, DYSLIPIDEMIA, OBESITY AND INFLAMMATORY DISORDERS

PE2004000361A 2003-04-15 2004-04-12 ALPHA CARBOXYL ACIDS SUBSTITUTED AS PPAR MODULATORS PE20050415A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46321303P 2003-04-15 2003-04-15

Publications (1)

Publication Number Publication Date
PE20050415A1 true PE20050415A1 (en) 2005-06-13

Family

ID=33300053

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000361A PE20050415A1 (en) 2003-04-15 2004-04-12 ALPHA CARBOXYL ACIDS SUBSTITUTED AS PPAR MODULATORS

Country Status (25)

Country Link
EP (1) EP1615899A1 (en)
JP (1) JP2006523671A (en)
KR (1) KR20060009846A (en)
CN (1) CN1805943A (en)
AP (1) AP2005003418A0 (en)
AR (1) AR044514A1 (en)
AU (1) AU2004230316A1 (en)
BR (1) BRPI0409429A (en)
CA (1) CA2521915A1 (en)
CL (1) CL2004000800A1 (en)
EA (1) EA200501462A1 (en)
EC (1) ECSP056105A (en)
IS (1) IS8033A (en)
MA (1) MA27764A1 (en)
MX (1) MXPA05010967A (en)
NL (1) NL1025946C2 (en)
NO (1) NO20055370L (en)
OA (1) OA13157A (en)
PA (1) PA8600201A1 (en)
PE (1) PE20050415A1 (en)
TN (1) TNSN05262A1 (en)
TW (1) TW200510353A (en)
UY (1) UY28266A1 (en)
WO (1) WO2004092145A1 (en)
ZA (1) ZA200508362B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006145872A (en) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) SUBSTITUTED TRIAZOLES AS PPAR MODULATORS AND METHODS FOR PRODUCING THEM
UA92746C2 (en) 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
US8962825B2 (en) 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
RU2480453C2 (en) 2007-03-08 2013-04-27 Альбирео Аб New compounds
EA200901573A1 (en) 2007-05-22 2010-04-30 Ачиллион Фармасьютикалз, Инк. Heteroaryl Thiazole Substituents
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
US8134000B2 (en) 2008-07-14 2012-03-13 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
JP5586692B2 (en) 2009-06-08 2014-09-10 ギリアード サイエンシーズ， インコーポレイテッド Alkanoylaminobenzamidoaniline HDAC inhibitor compound
NZ596783A (en) 2009-06-08 2014-01-31 Gilead Sciences Inc Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
DE102010055499A1 (en) * 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Preparing bendamustine alkyl ester compounds, comprises reacting substituted 2-((2-hydroxy-ethyl)-phenyl-amino)-ethanol compounds with a mixture comprising carbonyl amine compounds and sulfonyl compounds, or diketo compounds
RU2014121984A (en) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. BENZENESULPHONAMIDE COMPOUNDS AND THEIR APPLICATION AS A THERAPEUTIC MEDICINES
BR112014010368A2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaryl ether sulfonamides and their use as therapeutic agents
FR2982858B1 (en) * 2011-11-18 2013-11-29 Rhodia Operations PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS
FR2984322B1 (en) * 2011-12-16 2013-12-20 Rhodia Operations PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS
MX2014014234A (en) 2012-05-22 2015-05-07 Genentech Inc N-substituted benzamides and their use in the treatment of pain.
KR101663436B1 (en) 2012-07-06 2016-10-06 제넨테크, 인크. N-substituted benzamides and methods of use thereof
RU2015143906A (en) 2013-03-14 2017-04-18 Дженентек, Инк. SUBSTITUTED TRIAZOLOPYRIDINES AND WAYS OF THEIR APPLICATION
MX2015010775A (en) 2013-03-15 2016-04-25 Genentech Inc Substituted benzoxazoles and methods of use thereof.
CA2931732A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
CN106715418A (en) 2014-07-07 2017-05-24 基因泰克公司 Therapeutic compounds and methods of use thereof
BR112017024853A2 (en) 2015-05-22 2018-08-07 Genentech Inc compound, pharmaceutical composition, method for treating a disease or condition in a mammal, for treating itching in a mammal, for treating or prophylaxis and use of a compound
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP6987746B2 (en) 2015-09-28 2022-01-05 ジェネンテック， インコーポレイテッド Therapeutic compounds and their usage
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
CA3039853A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
AR114263A1 (en) 2018-02-26 2020-08-12 Genentech Inc THERAPEUTIC COMPOUNDS AND METHODS TO USE THEM
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1088824T3 (en) * 1999-09-30 2004-04-13 Pfizer Prod Inc Bicyclic pyrrolylamides as glycogen phosphorylase inhibitors
WO2002064130A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds

Also Published As

Publication number Publication date
NL1025946C2 (en) 2005-02-01
BRPI0409429A (en) 2006-04-18
AU2004230316A1 (en) 2004-10-28
WO2004092145A8 (en) 2005-05-12
ECSP056105A (en) 2006-03-01
NO20055370L (en) 2006-01-12
CN1805943A (en) 2006-07-19
CA2521915A1 (en) 2004-10-28
AR044514A1 (en) 2005-09-14
ZA200508362B (en) 2006-11-29
EA200501462A1 (en) 2006-04-28
OA13157A (en) 2006-12-13
UY28266A1 (en) 2004-11-30
KR20060009846A (en) 2006-02-01
NO20055370D0 (en) 2005-11-14
MXPA05010967A (en) 2005-11-28
IS8033A (en) 2005-09-15
MA27764A1 (en) 2006-02-01
TW200510353A (en) 2005-03-16
JP2006523671A (en) 2006-10-19
CL2004000800A1 (en) 2005-03-04
PA8600201A1 (en) 2005-02-04
NL1025946A1 (en) 2004-10-18
EP1615899A1 (en) 2006-01-18
TNSN05262A1 (en) 2007-07-10
AP2005003418A0 (en) 2005-12-31
WO2004092145A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
PE20050415A1 (en) ALPHA CARBOXYL ACIDS SUBSTITUTED AS PPAR MODULATORS
DE60222006T2 (en) Heterocyclic compounds and their uses
DE60315603T2 (en) MODULATORS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
US7071335B2 (en) 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain
JP5695906B2 (en) Cyclic urea inhibitor of 11β-hydroxysteroid dehydrogenase 1
NO20074324L (en) Substituted arylamine compositions and their use as 5-HT6 modulators
PE20060693A1 (en) NEW DERIVATIVES OF TRIFLUOROMETANSULFONANILIDE OXAMIDE ETER
JP5400030B2 (en) N-substituted thiomorpholine derivatives and their pharmaceutical use as inhibitors of dipeptidyl peptidase IV
PE20081485A1 (en) SULFONAMIDE DERIVATIVES
PE20050018A1 (en) HETEROAROMATIC PENTACYCLIC COMPOUND AS INHIBITOR OF PROTEIN TYROSINE PHOSPHATASE 1B (PTB1B)
JP2009280595A5 (en)
BRPI0706790A2 (en) trisubstituted amine compound
PE20081059A1 (en) DERIVATIVES OF PYRIMIDINES AS INHIBITORS OF THE ACTIVITY OF BRUTON'S TYROSINE KINASE (BTK)
ATE440091T1 (en) ANTIDIABETIC BICYCLIC COMPOUNDS
KR20120114355A (en) Compounds and methods
ECSP11010782A (en) DERIVATIVES OF 4,5-DIHIDRO-OXAZOL-2-ILO
JP2016512499A (en) GPR120 agonist for treating type II diabetes
FR2890072A1 (en) New pyrrolopyridine derivatives are peroxisome proliferator activated receptor activators useful to treat e.g. hypertriglyceridimia, hyperlipidemia, hypercholesterolemia and diabetes
PE20080267A1 (en) TRIARYLIC COMPOUNDS AND THEIR DERIVATIVES
PE20090999A1 (en) NEW DERIVATIVES OF METHYL-BENZIMIDAZOLE
CN103547570A (en) Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists
SK76295A3 (en) Aminomethylindans, - benzofuranes and - benzothiophenes and their use
PE20110773A1 (en) TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND SUBSTITUTE PIPERIDINONE, AND THEIR PREPARATION
Seto et al. Design, Synthesis, and Structure− Activity Relationship Studies of Novel 2, 4, 6-Trisubstituted-5-pyrimidinecarboxylic Acids as Peroxisome Proliferator-Activated Receptor γ (PPARγ) Partial Agonists with Comparable Antidiabetic Efficacy to Rosiglitazone
Ella-Menye et al. New synthesis of chiral 1, 3-oxazinan-2-ones from carbohydrate derivatives

Legal Events

Date Code Title Description
FC Refusal